Patients. Do they know enough to take control?

2 min read

Do patients with greater knowledge manage their disease better? This question was addressed in a cross sectional study presented at ERS2025. A new framework from Professor Celeste Porsbjerg’s team redefines remission in severe asthma by focusing on disease activity, not damage. Early, targeted treatment during the “at-risk asthma” phase may prevent lasting harm.

2025 ERS AMSTERDAM

Part of: Nursing role in global respiratory health

The Impact of COPD knowledge on symptoms severity, quality of life and inhaler technique.Presented by Maria Granados Santiago (Spain)

Health literacy – ability to understand health

Different patients are typically at different levels of understanding of health and disease (i.e. health literacy): This can, in turn, impact how long it takes realize that what they are experiencing is not normal and seek care, and then how well they can manage treatments and to understand what they can do to improve quality of life despite their disease.

Disease knowledge – linked to less disease burden

A Spanish cross sectional study aimed to evaluate to whether dyspnea, quality of life and correct inhaler technique can be linked to the patients’ level of knowledge about COPD.

Participants were assessed upon hospital admission, evaluating dyspnoea, inhaler technique skills, disease impact on autonomy and overall quality of life. They were also assessed on COPD knowledge and separated into two groups: those with superficial understanding and those with a more comprehensive understanding (COPD-Q score 8 or more).

Invest in patient education

Patients with greater knowledge had significantly fewer symptoms, rated quality of life higher and used their inhalers more effectively. These findings underline that interventions to improve the patient’s knowledge about their disease, such as providing patient education, are an important part of optimized disease management.

Reference
  1. Puente-Maestu L, Calle M, Rodríguez-Hermosa JL, et al. Health literacy and health outcomes in chronic obstructive pulmonary disease. Respir Med. 2016;115:78-82. doi:10.1016/j.rmed.2016.04.016

ID 17198-13.10.2025

Chiesi Logo – 1. website_Primary_pant_RGB

Chiesi er et familieeid legemiddelselskap grunnlagt i 1935. Vi tror på innovasjon, ansvar og menneskelig empati. Vår lidenskap er å forbedre livskvaliteten for pasienter over hele verden gjennom forskning, utvikling og bærekraftige løsninger. 

© 2026 Chiesi Pharma AB. Dette nettstedet er beregnet på helsepersonell i Norge.